Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    "Membranoproliferative glomerulonephritis type 2"
Show Display Options
Rank Status Study
1 Withdrawn Sulodexide Treatment in Patients With Dense Deposit Disease
Condition: Dense Deposit Disease
Intervention: Drug: Sulodexide
2 Unknown  Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Conditions: Dense Deposit Disease;   Membranoproliferative Glomerulonephritis
Intervention: Drug: Eculizumab
3 Terminated Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
Conditions: Dense Deposit Disease;   Membranoproliferative Glomerulonephritis Type II;   C3 Glomerulonephritis
Intervention: Drug: CDX-1135
4 Withdrawn TP10 Use in Patients With C3 Glomerulopathy (C3G)
Condition: Dense Deposit Disease
Intervention: Drug: TP10
5 Recruiting OMS721 Treatment of Steroid-Dependent Glomerulopathies
Conditions: Steroid-Dependent IgAN;   Lupus Nephritis;   MN;   C3G
Intervention: Biological: OMS721

Study has passed its completion date and status has not been verified in more than two years.